Kidney cancer treatment rankings changed across survival time windows
An analysis of initial treatments for metastatic clear cell kidney cancer found that survival rankings depended on follow-up time and the outcome assessed.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Treatment rankings changed with the time window used to assess survival. Nivolumab plus cabozantinib ranked strongly earlier, while ipilimumab plus nivolumab ranked highest later. Pembrolizumab plus lenvatinib ranked highest for survival without disease progression. These are comparative rankings from reconstructed trial data, and the abstract provides no treatment-difference estimates or confidence intervals.
An abstract-based ranking cannot determine the best treatment for an individual. The authors relied on patient data reconstructed from survival curves and reported differences across trials, limiting confidence in comparisons.
Why timing mattered
The review asked whether standard hazard-ratio comparisons adequately captured benefits that change over time. An underlying statistical assumption often failed, and the researchers used restricted mean survival time to compare treatment patterns across follow-up windows.
A subgroup result remained uncertain
Among patients classified as favorable risk, avelumab plus axitinib had an encouraging long-term pattern that was not statistically significant. The abstract therefore does not establish a benefit for that subgroup.
The original publication
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis.
Fukushima H, Yajima S, Chen W et al.
Target Oncol · 2026
- PubMed ID
- 41575641
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.